Good evening :)
Place Order
Add to Watchlist

Alkem Laboratories Ltd

ALKEM

Alkem Laboratories Ltd

ALKEM
Health CarePharmaceuticals
MidcapWith a market cap of ₹56,298 cr, stock is ranked 151
Low RiskStock is 1.88x as volatile as Nifty
4,719.550.23% (+10.95)
4,719.550.23% (+10.95)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹56,298 cr, stock is ranked 151
Low RiskStock is 1.88x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹56,298 cr, stock is ranked 151
Low RiskStock is 1.88x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
26.155.250.85%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
48.416.160.55%

Forecast & Ratings

Detailed Forecast 
40%
Analysts have suggested that investors can buy this stock

from 20 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.

Investor Presentation

View older 

Feb 7, 2025

PDF
View Older Presentations
PE Ratio
42.44
1Y Return
13.24%
Buy Reco %
85.29
PE Ratio
28.40
1Y Return
0.99%
Buy Reco %
72.73
PE Ratio
62.52
1Y Return
17.26%
Buy Reco %
70.37
PE Ratio
18.16
1Y Return
3.43%
Buy Reco %
40.63
PE Ratio
52.25
1Y Return
14.92%
Buy Reco %
80.00
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 3.39% to 3.43%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5,164.555,799.546,516.597,444.898,448.589,098.2210,796.8411,815.3412,978.4213,192.54
Raw Materialssubtract2,068.322,511.132,477.742,941.333,574.893,832.304,715.774,444.474,923.4610,246.27
Power & Fuel Costsubtract66.3386.34112.64121.48130.14129.95162.96163.94162.58
Employee Costsubtract861.081,003.851,191.641,362.461,505.491,621.031,962.712,131.352,201.01
Selling & Administrative Expensessubtract879.561,014.861,175.611,288.441,412.401,224.581,722.202,163.712,163.46
Operating & Other expensessubtract196.3072.40434.62528.71248.05114.7632.591,189.321,093.07
Depreciation/Amortizationsubtract93.31101.17143.03193.18252.76274.58303.96310.42299.30328.10
Interest & Other Itemssubtract71.2445.1655.3354.6365.0658.9252.37107.36112.41120.14
Taxes & Other Itemssubtract186.8272.60295.04194.15132.72257.08198.66320.60227.36344.85
EPS62.0274.6152.7763.6194.26132.57137.6382.31150.19180.08
DPS12.7015.0013.0016.0025.0030.0034.0050.0040.0040.00
Payout ratio0.200.200.250.250.270.230.250.610.270.22

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 13PDF
Feb 4PDF
Nov 12PDF
FY 2023

Annual Report Unavailable

Investor Presentation

May 19PDF
Feb 10PDF
Nov 11PDF
Aug 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 7PDF
Nov 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alkem Laboratories Ltd31.355.250.85%
Sun Pharmaceutical Industries Ltd42.446.060.80%
Cipla Ltd28.404.370.90%
Torrent Pharmaceuticals Ltd62.5215.100.92%

Price Comparison

Compare ALKEM with any stock or ETF
Compare ALKEM with any stock or ETF
ALKEM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.12%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding55.66%14.01%4.00%10.15%16.18%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '246.03%8.49%9.11%8.69%9.02%10.15%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alkem Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.9893%1.94%0.29%13/85 (0)
0.9448%1.01%-0.13%22/224 (-3)
0.8801%2.66%-0.15%8/116 (+1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Alkem Laboratories Ltd

Loading...
Growth & Income

Growth & Income

Created by Windmill Capital

ALKEM's Wtg.
7.00%
CAGR
26.71%

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ALKEM has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.85%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.50 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

Cash Dividend

Ex DateEx DateFeb 14, 2025

Interim
Interim | Div/Share: ₹37.00

Dividend/Share

₹37.00

Ex DateEx Date

Feb 14, 2025

Past Dividends

Cash Dividend

Ex DateEx DateAug 9, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 9, 2024

Cash Dividend

Ex DateEx DateFeb 16, 2024

Interim
Interim | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Feb 16, 2024

Cash Dividend

Ex DateEx DateAug 10, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 10, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Interim
Interim | Div/Share: ₹15.00

Dividend/Share

₹15.00

Ex DateEx Date

Feb 17, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Special
Special | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Feb 17, 2023

News & Opinions
Earnings
Alkem Laboratories consolidated net profit rises 5.19% in the December 2024 quarter

Net profit of Alkem Laboratories rose 5.19% to Rs 625.82 crore in the quarter ended December 2024 as against Rs 594.96 crore during the previous quarter ended December 2023. Sales rose 1.52% to Rs 3374.28 crore in the quarter ended December 2024 as against Rs 3323.87 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3374.283323.87 2 OPM %22.5121.29 - PBDT816.35775.77 5 PBT731.07706.21 4 NP625.82594.96 5 Powered by Capital Market - Live

6 days agoCapital Market - Live
Corporate
Board of Alkem Laboratories recommends interim dividend

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 7 February 2025, inter alia, have recommended the interim dividend of Rs 37 per equity Share (i.e. 1850%) , subject to the approval of the shareholders.Powered by Capital Market - Live

6 days agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd soars 0.53%, gains for fifth straight session

Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 5283.4, up 0.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 23583.2. The Sensex is at 77886.15, down 0.22%. Alkem Laboratories Ltd has slipped around 5% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 4.11% in last one month and is currently quoting at 22009.05, up 0.26% on the day. The volume in the stock stood at 55658 shares today, compared to the daily average of 90616 shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 5265.1, up 0.59% on the day. Alkem Laboratories Ltd is down 0.52% in last one year as compared to a 8.59% jump in NIFTY and a 19.15% jump in the Nifty Pharma index.The PE of the stock is 29.06 based on TTM earnings ending September 24.Powered by Capital Market - Live

6 days agoCapital Market - Live
Corporate
Alkem Laboratories announces board meeting date

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Alkem Labs gains after inking agreement to sell MP-based facility for Rs 133.5 crore

The said transaction is part of the company's ongoing initiative of networking strategy and optimization of manufacturing facilities. The sale includes all rights, title and interest in the leasehold land, factory building, assets and liabilities etc. associated with the said facility. The business transfer agreement has been executed between the company and Rubicon Research on a slump sale basis. The company would receive a cash consideration of Rs 133.5 crore. Rubicon Research is engaged in the business of development, manufacture, distribution and sale of pharmaceutical formulations. Rubicon does not belong to the promoter/ promoter group of Alkem Laboratories. Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd gains for third straight session

Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 5567.2, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 23803.900390625. The Sensex is at 78735.73, up 0.05%. Alkem Laboratories Ltd has slipped around 2.21% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 3.31% in last one month and is currently quoting at 23008.35, up 0.8% on the day. The volume in the stock stood at 1.05 lakh shares today, compared to the daily average of 1.21 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 5571.1, up 1.21% on the day. Alkem Laboratories Ltd is up 8.73% in last one year as compared to a 9.48% jump in NIFTY and a 37.57% jump in the Nifty Pharma index.The PE of the stock is 30.31 based on TTM earnings ending September 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alkem Lab jumps after jointly with arm inks pact to invest Rs 1.95-cr in Sunsure Solarpark

The company along with Enzene Bioscience entered into share subscription and shareholder agreement. Sunsure Solarpark is a wholly owned subsidiary of Sunsure Energy is engaged in the business of generation, production and distribution of electricity from renewable energy sources. The companies will acquire 26% stake in Sunsure Solarpark for total consideration of Rs 1.95 crore to purchase renewable power source in compliance with the environmental social governance thereby resulting in reduced power/ electricity costs. In order to comply with regulatory requirement, the company and Enzene shall, being the captive users, collectively hold not less than 26% stake in the equity share capital of Sunsure Solarpark on a fully diluted basis and consume the solar energy generated therefrom, throughout the term of Share Subscription and Shareholder's Agreement and certain other transaction documents. Total contribution for the acquisition of equity share capital of Sunsure Solarpark will be Rs 1.95 crore, with Alkem Laboratories contributing Rs 93.60 lakh while Enzene Bioscience contributing Rs 1.01 crore. Alkem will hold 26% stake in Sunsure Solarpark while Enzene Bioscience will hold a 13.52% stake. The said transaction will be completed by the end of April 2025. Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Alkem Laboratories approves transfer of its trade generics biz to Alkem Wellness

The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India. The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd spurts 1.4%

Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5721.55, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Alkem Laboratories Ltd has dropped around 1.32% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 82592 shares today, compared to the daily average of 5.98 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 5751.2, up 1.67% on the day. Alkem Laboratories Ltd is up 24.03% in last one year as compared to a 16.91% spurt in NIFTY and a 38.53% spurt in the Nifty Pharma index.The PE of the stock is 31.19 based on TTM earnings ending September 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Alkem Laboratories consolidated net profit rises 10.98% in the September 2024 quarter

Net profit of Alkem Laboratories rose 10.98% to Rs 688.64 crore in the quarter ended September 2024 as against Rs 620.52 crore during the previous quarter ended September 2023. Sales declined 0.74% to Rs 3414.67 crore in the quarter ended September 2024 as against Rs 3440.17 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3414.673440.17 -1 OPM %22.0521.71 - PBDT859.17779.60 10 PBT780.26705.70 11 NP688.64620.52 11 Powered by Capital Market - Live

3 months agoCapital Market - Live